Skip to main content

Series A · 2026-11-12 · Healthcare

Orakl Oncology raises $32.4M

65
AI Score
Amount
$32.4M
Round
Series A
Lead
Norrsken VC, Singular
HQ
FR
Why it matters: The round shows investors backing a platform that pairs patient-derived tumor organoids with AI to forecast trial outcomes, a concrete bet on cutting late-stage oncology failure.

Orakl Oncology, a French TechBio spun out of the Gustave Roussy Institute, raised a €30M ($34M) Series A co-led by Norrsken VC and Singular.

Participants:
InfraVia Capital Partners, Serena, Patient Autonome Fund, Bpifrance, Teampact Ventures, Plug and Play, Verve Ventures VC, Speedinvest, HCVC, Dorothy Chou, Thomas Wolf, Stanislas Polu

Other rounds by Orakl Oncology

Deal Dossier PRO

Pro feature
Deal Dossier for Orakl Oncology

Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.

Generate dossier — Pro
Already Pro? Sign in · See plans

Figures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).

Recent Healthcare rounds

Browse all deals in the funding database →

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing